PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1735794
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1735794
Global Brucellosis Vaccine Market Size study, by Application (Sheep, Cattle, Goat), by Type (RB51 Vaccine, S19 Vaccine, B19 Vaccine), by Distribution Channel and Regional Forecasts 2022-2032
The Global Brucellosis Vaccine Market is valued at approximately USD 0.24 billion in 2023 and is expected to expand at a steady CAGR of 4.59% over the forecast period 2024-2032. Brucellosis, a contagious zoonotic disease with profound economic implications in livestock production, has necessitated consistent and widespread vaccination initiatives globally. The disease primarily afflicts cattle, sheep, and goats, causing reproductive failures and productivity losses. Brucellosis vaccines, notably live attenuated strains like RB51 and S19, play a pivotal role in disease eradication campaigns and biosecurity frameworks. With a growing awareness of zoonotic transmission risks and the need for sustainable livestock health, government-backed veterinary health programs are actively bolstering demand for effective brucellosis immunization solutions.
The rising global emphasis on food safety, public health, and livestock trade compliance is driving the adoption of vaccination strategies against brucellosis. National eradication efforts in countries with endemic prevalence, such as India, Brazil, and parts of Africa, are catalyzing market growth through policy-mandated immunization drives. Additionally, the agricultural sector's transition toward preventive healthcare, especially in commercial dairy and meat production, is creating sustained demand for brucellosis vaccines across both developed and developing economies. However, logistical challenges in cold chain maintenance, vaccine access in remote regions, and occasional resistance from unorganized farming communities remain hurdles to seamless market expansion.
Manufacturers are innovating around vaccine formulations to enhance thermal stability, improve safety profiles, and reduce the risk of post-vaccination complications. Technological advancements are also streamlining the traceability of livestock vaccination records, ensuring better compliance with international trade norms. With the emergence of combination vaccines and species-specific immunization protocols, product diversification is reshaping the competitive landscape. Furthermore, increased collaboration between public institutions and private veterinary pharmaceutical companies is augmenting research initiatives and distribution networks-especially in regions with high brucellosis incidence rates.
Geographically, North America maintains a significant footprint in the brucellosis vaccine market, supported by sophisticated livestock management systems, stringent animal health regulations, and robust veterinary infrastructure. Europe closely trails, with extensive disease control mandates and research funding. Meanwhile, Asia Pacific is anticipated to witness the fastest growth rate owing to the sheer scale of its livestock population, expanding veterinary outreach, and intensifying government-led disease eradication programs. Latin America and the Middle East & Africa present promising growth potential, driven by increasing awareness, improving agricultural productivity initiatives, and rising investments in animal health services.
Major market player included in this report are:
- Indian Immunologicals Ltd.
- Colorado Serum Company
- Boehringer Ingelheim
- Hester Biosciences
- CZ Veterinaria
- Bioveta
- Zoetis Inc.
- Merck Animal Health
- Ceva Sante Animale
- Vaxxinova
- Elanco Animal Health
- Bimeda Animal Health
- Virbac
- AVImark
- Phibro Animal Health Corporation
The detailed segments and sub-segment of the market are explained below:
By Application
- Sheep
- Cattle
- Goat
By Type
- RB51 Vaccine
- S19 Vaccine
- B19 Vaccine
By Distribution Channel
- Veterinary Hospitals
- Veterinary Clinics
- Government Agencies
- Online Pharmacies
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- RoMEA
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Brucellosis Vaccine Market Executive Summary
- 1.1. Global Brucellosis Vaccine Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Application
- 1.3.2. By Type
- 1.3.3. By Distribution Channel
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Brucellosis Vaccine Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Producer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Stakeholder Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Brucellosis Vaccine Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Government-backed Eradication Programs
- 3.1.2. Rising Focus on Food Safety and Zoonotic Risk Mitigation
- 3.1.3. Preventive Veterinary Healthcare Adoption
- 3.2. Market Challenges
- 3.2.1. Cold Chain and Logistical Constraints
- 3.2.2. Limited Access in Remote and Small-holder Farms
- 3.2.3. Vaccine Hesitancy in Unorganized Livestock Sectors
- 3.3. Market Opportunities
- 3.3.1. Development of Thermostable and Combination Vaccines
- 3.3.2. Digital Traceability and Record-keeping Solutions
- 3.3.3. Public-Private Partnerships to Expand Outreach
Chapter 4. Global Brucellosis Vaccine Market Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunity
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspective
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Brucellosis Vaccine Market Size & Forecasts by Application 2022-2032
- 5.1. Segment Dashboard
- 5.2. Revenue Trend Analysis by Application, 2022 & 2032 (USD Million)
- 5.2.1. Sheep
- 5.2.2. Cattle
- 5.2.3. Goat
Chapter 6. Global Brucellosis Vaccine Market Size & Forecasts by Type 2022-2032
- 6.1. Segment Dashboard
- 6.2. Revenue Trend Analysis by Type, 2022 & 2032 (USD Million)
- 6.2.1. RB51 Vaccine
- 6.2.2. S19 Vaccine
- 6.2.3. B19 Vaccine
Chapter 7. Global Brucellosis Vaccine Market Size & Forecasts by Distribution Channel 2022-2032
- 7.1. Segment Dashboard
- 7.2. Revenue Trend Analysis by Distribution Channel, 2022 & 2032 (USD Million)
- 7.2.1. Veterinary Hospitals
- 7.2.2. Veterinary Clinics
- 7.2.3. Government Agencies
- 7.2.4. Online Pharmacies
Chapter 8. Global Brucellosis Vaccine Market Size & Forecasts by Region 2022-2032
- 8.1. North America Market
- 8.1.1. U.S. Market
- 8.1.1.1. Application breakdown, 2022-2032
- 8.1.1.2. Type breakdown, 2022-2032
- 8.1.2. Canada Market
- 8.1.1. U.S. Market
- 8.2. Europe Market
- 8.2.1. U.K. Market
- 8.2.2. Germany Market
- 8.2.3. France Market
- 8.2.4. Spain Market
- 8.2.5. Italy Market
- 8.2.6. Rest of Europe Market
- 8.3. Asia Pacific Market
- 8.3.1. China Market
- 8.3.2. India Market
- 8.3.3. Japan Market
- 8.3.4. Australia Market
- 8.3.5. South Korea Market
- 8.3.6. Rest of APAC Market
- 8.4. Latin America Market
- 8.4.1. Brazil Market
- 8.4.2. Mexico Market
- 8.4.3. Rest of Latin America Market
- 8.5. Middle East & Africa Market
- 8.5.1. Saudi Arabia Market
- 8.5.2. South Africa Market
- 8.5.3. Rest of MEA Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. Indian Immunologicals Ltd.
- 9.1.2. Colorado Serum Company
- 9.1.3. Boehringer Ingelheim
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. Indian Immunologicals Ltd.
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Market Strategies
- 9.3.2. Colorado Serum Company
- 9.3.3. Boehringer Ingelheim
- 9.3.4. Hester Biosciences
- 9.3.5. CZ Veterinaria
- 9.3.6. Bioveta
- 9.3.7. Zoetis Inc.
- 9.3.8. Merck Animal Health
- 9.3.9. Ceva Sante Animale
- 9.3.10. Vaxxinova
- 9.3.11. Elanco Animal Health
- 9.3.12. Bimeda Animal Health
- 9.3.13. Virbac
- 9.3.14. AVImark
- 9.3.15. Phibro Animal Health Corporation
- 9.3.1. Indian Immunologicals Ltd.
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
